Keck School Faculty

Radu O. Minea

Radu O. Minea

Assistant Professor of Research Neurological Surgery
Surgery
HMR 2011 Zonal Avenue 414 Health Sciences Campus Los Angeles

Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia Cancers (Basel). 2021 Jul 06; 13(14). . View in PubMed

Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas PLoS One. 2020; 15(9):e0238238. . View in PubMed

Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro Ther Adv Med Oncol. 2019; 11:1758835919891567. . View in PubMed

A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice Molecules. 2018 Nov 08; 23(11). . View in PubMed

Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo Cancers (Basel). 2018 Sep 28; 10(10). . View in PubMed

Multimeric disintegrin protein polymer fusions that target tumor vasculature Biomacromolecules. 2014 Jul 14; 15(7):2347-58. . View in PubMed

Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential Toxicon. 2012 Mar 15; 59(4):472-86. . View in PubMed

Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities PLoS One. 2010 Jun 03; 5(6):e10929. . View in PubMed

The use of pepsin in receptor internalization assays Biochem Biophys Res Commun. 2009 Oct 16; 388(2):240-6. . View in PubMed

Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent Pathophysiol Haemost Thromb. 2005; 34(4-5):177-83. . View in PubMed

Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression Mol Cancer Ther. 2004 Apr; 3(4):499-511. . View in PubMed

sc ctsi logoPowered by SC CTSI